Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paclitaxel + anthracycline
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
Paclitaxel + anthracycline refers to a chemotherapy regimen combining the taxane class drug paclitaxel with an anthracycline (most commonly doxorubicin or epirubicin). This combination is primarily used in the treatment of metastatic and advanced breast cancer. Paclitaxel stabilizes microtubules and inhibits cell division, while anthracyclines intercalate DNA and inhibit topoisomerase II, leading to DNA damage and apoptosis. The regimen has demonstrated high response rates in clinical trials but is associated with risks of cardiotoxicity—especially when doxorubicin is used—necessitating careful cardiac monitoring. Substituting epirubicin for doxorubicin can reduce cardiac toxicity while maintaining efficacy[1][3][4].
- Brand names
- Taxol
- Other names
- paclitaxel and anthracycline combinationtaxane-anthracycline combinationpaclitaxel-doxorubicinpaclitaxel-epirubicin
02
Targets
TUBB (Tubulin (alpha and beta subunits))TOP2A (DNA topoisomerase II)DNA
Beyond the preview
Go deeper on paclitaxel + anthracycline.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paclitaxel + anthracycline.